Pages that link to "Q45264009"
The following pages link to Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma (Q45264009):
Displaying 50 items.
- Targeted therapy for advanced renal cell carcinoma (Q24242946) (← links)
- Contemporary Treatment of Metastatic Renal Cell Carcinoma (Q26740594) (← links)
- Chinese guidelines on the management of renal cell carcinoma (2015 edition) (Q26772206) (← links)
- Sequence of treatment in locally advanced and metastatic renal cell carcinoma (Q26773653) (← links)
- Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials (Q26822790) (← links)
- Clinical biomarkers of response in advanced renal cell carcinoma (Q26852564) (← links)
- Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis (Q27003304) (← links)
- Individualising treatment choices in a crowded treatment algorithm (Q27023669) (← links)
- Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? (Q28068710) (← links)
- Sunitinib in the treatment of metastatic renal cell carcinoma (Q28072057) (← links)
- Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study (Q28547506) (← links)
- Immunotherapy for metastatic renal cell carcinoma (Q30234458) (← links)
- Renal cell cancer: overview of the current therapeutic landscape. (Q30248354) (← links)
- Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. (Q30249335) (← links)
- Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature (Q30565687) (← links)
- Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature (Q30711589) (← links)
- Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature (Q30942279) (← links)
- Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma (Q31108636) (← links)
- Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. (Q33166002) (← links)
- Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis (Q33404547) (← links)
- Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study (Q33406542) (← links)
- A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. (Q33415840) (← links)
- Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis (Q33430139) (← links)
- Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy (Q33431578) (← links)
- Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules (Q33588722) (← links)
- (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor (Q33590458) (← links)
- Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study (Q33606102) (← links)
- Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy? (Q33631414) (← links)
- Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients (Q33633424) (← links)
- Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial (Q33716744) (← links)
- Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials (Q33849805) (← links)
- STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma (Q33903747) (← links)
- Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. (Q33990928) (← links)
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial (Q33997879) (← links)
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials (Q34032864) (← links)
- Modeling the relationship between progression-free survival and overall survival: the phase II/III trial (Q34040130) (← links)
- The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients (Q34086952) (← links)
- Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma (Q34105997) (← links)
- Pazopanib for the treatment of patients with advanced renal cell carcinoma (Q34207205) (← links)
- A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. (Q34256006) (← links)
- Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis (Q34272887) (← links)
- Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy (Q34371248) (← links)
- Sunitinib and other targeted therapies for renal cell carcinoma (Q34621802) (← links)
- Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies (Q34627828) (← links)
- Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma (Q34658963) (← links)
- Immunologics and chemotherapeutics for renal cell carcinoma. (Q34660154) (← links)
- Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting (Q34660431) (← links)
- Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial (Q34806694) (← links)
- Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma (Q35064011) (← links)
- Future directions in renal cell carcinoma: 2011 and beyond (Q35152107) (← links)